WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Ozempic maker sues US rival over ad campaign — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 20 fonti

Ozempic maker sues US rival over ad campaign

Novo Nordisk has claimed that Eli Lilly is using bad data to compare the companies' weight-loss and diabetes products in its ads.

Raccontata da

biopharmadive.com

www1.folha.uol.com.br

eu.usatoday.com

economictimes.indiatimes.com

efe.com+8 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

dw.comStai leggendo1 mese fa

Ozempic maker sues US rival over ad campaign

Novo Nordisk has claimed that Eli Lilly is using bad data to compare the companies' weight-loss and diabetes products in its ads.

Timeline cronologica

martedì 21 luglio 2026·forbes.com
Ozempic Maker Novo Nordisk Sues Eli Lilly For Deceptive Advertising
The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.
martedì 21 luglio 2026·biopharmadive.com
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that…

1 mese fa

Ozempic Maker Novo Nordisk Sues Eli Lilly For Deceptive Advertising

The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.

Leggi questa versione → originale

france24.com1 mese fa

Pharma heavyweights clash over anti-obesity drug ads

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes…

Leggi questa versione → originale

channelnewsasia.com1 mese fa

Pharma heavyweights Novo Nordisk and Eli Lilly clash over anti-obesity drug ads

Novo Nordisk said Eli Lilly's ads uses outdated research and leave out important information, which could mislead consumers.

Leggi questa versione → originale

nbcnews.com1 mese fa

Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.

Leggi questa versione → originale

eluniversal.com.mx1 mese fa

Novo Nordisk, fabricante de Ozempic y Wegovy, demanda a Eli Lilly; acusa publicidad engañosa sobre…

La compañía danesa critica las comparaciones de sus tratamientos con los medicamentos estrella de su competidor estadounidense, Mounjaro y Zepbound

Leggi questa versione → originale

martedì 21 luglio 2026·

index.hr

Proizvođač Ozempica tužio konkurenta

FARMACEUTSKA tvrtka Novo Nordisk tuži konkurenta Eli Lilly zbog, kako navodi, lažnog prikazivanja njegovih lijekova za mršavljenje kao superiornijih na temelju zastarjelih studija.

martedì 21 luglio 2026·

www1.folha.uol.com.br

Dona do Ozempic acusa criadora do Mounjaro de fazer propaganda com dados falsos sobre eficácia

Eli Lilly não responde a pedido de comentário após processo da Novo Nordisk nos EUA

martedì 21 luglio 2026·

statnews.com

Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’

Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.

martedì 21 luglio 2026·

cnbc.com

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.

martedì 21 luglio 2026·

nbcnews.com

Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says…

martedì 21 luglio 2026·

eu.usatoday.com

Wegovy maker sues rival Eli Lilly over 'deliberately false' GLP-1 ads

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.

martedì 21 luglio 2026·

economictimes.indiatimes.com

Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its…

martedì 21 luglio 2026·

zerohedge.com

GLP-1 Fight: Novo Sues Eli Lilly Over Nationwide "Deceptive Advertising" Campaign

"Through this action, Novo Nordisk is seeking a permanent injunction requiring Lilly to pull its misleading comparative advertising across all platforms... "

martedì 21 luglio 2026·

france24.com

Pharma heavyweights clash over anti-obesity drug ads

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing…

martedì 21 luglio 2026·

efe.com

El fabricante de Ozempic demanda a su rival Eli Lilly por publicidad engañosa - EFE

Novo Nordisk, fabricante del medicamento contra la obesidad Ozempic, demanda a su rival Eli Lilly por publicidad engañosa.

martedì 21 luglio 2026·

fiercepharma.com

Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads

Novo Nordisk has accused rival Eli Lilly of runnin | Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public…

martedì 21 luglio 2026·

oglobo.globo.com

Briga das canetas emagrecedoras: dona do Ozempic processa fabricante do Mounjaro nos EUA por propaganda enganosa

Empresa dinamarquesa alega que a rival usou comparações com doses antigas do Wegovy para favorecer o Zepbound e pede a suspensão imediata da campanha

martedì 21 luglio 2026·

milanofinanza.it

Novo Nordisk porta Eli Lilly in tribunale: pubblicità ingannevole sui farmaci anti-obesità | MilanoFinanza News

La casa farmaceutica danese accusa la rivale americana di aver promosso Zepbound e Mounjaro con confronti «falsi e fuorvianti» rispetto a Wegovy e Ozempic. Nel mirino una campagna…

martedì 21 luglio 2026·

eluniversal.com.mx

Novo Nordisk, fabricante de Ozempic y Wegovy, demanda a Eli Lilly; acusa publicidad engañosa sobre medicamentos contra obesidad y diabetes

La compañía danesa critica las comparaciones de sus tratamientos con los medicamentos estrella de su competidor estadounidense, Mounjaro y Zepbound

martedì 21 luglio 2026·

ilpost.it

L'azienda Novo Nordisk, che produce l'Ozempic, ha fatto causa alla concorrente Eli Lilly per pubblicità ingannevole

La multinazionale danese Novo Nordisk, che produce l’Ozempic e il Wegovy – due farmaci utilizzati per contrastare il diabete e l’obesità (cambiano i dosaggi) – ha fatto causa…

martedì 21 luglio 2026·

dw.com

Ozempic maker sues US rival over ad campaign

Novo Nordisk has claimed that Eli Lilly is using bad data to compare the companies' weight-loss and diabetes products in its ads.

martedì 21 luglio 2026·

eldiario.es

Novo Nordisk, la creadora de Ozempic, demanda a su rival Eli Lilly en Estados Unidos por publicidad engañosa

La farmacéutica danesa acusa a su rival de emplear estudios desactualizados para decir que sus productos adelgazan más

martedì 21 luglio 2026·

upi.com

Novo Nordisk suing Eli Lilly over GLP-1 ‘outdated’ advertisements - UPI.com

Novo Nordisk, the maker of Wegovy, has filed a lawsuit on Tuesday against competitor Eli Lilly alleging that its GLP-1 advertisements are misleading.